ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,544 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentSchlierenMolecular Partners AG
Molecular Partners AG Logo
Verified· 4 sourcesTrust Score
Summary

About the company

The company develops innovative therapeutic compounds, in particular DARPins, for diseases with high unmet medical need, with a focus on ophthalmology and oncology.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.5/5

Molecular Partners AG

✓ Offered5
DARPin therapeutics
DARPin therapeutics, a new class of multifunctional protein medicines; development of tailored active ingredients with high affinity, specificity, multispecificity and scalable manufacturing.
Radio-DARPin therapeutics
Radio-DARPin therapeutics for targeted alpha radiotherapy of tumors; precise delivery of radioactive payloads, reduction of nephrotoxicity, increased tumor uptake.
Switch-DARPin therapeutics
Switch-DARPin therapeutics for conditional, tumor-localized immunactivation; logic-controlled T-cell engagers and other multispecific candidates with target binding to tumor antigens.
Oncology pipeline therapeutics
Cancer therapeutics in clinical and preclinical development, including MP0712 for SCLC and neuroendocrine tumors, MP0726 for ovarian cancer, MP0317 for advanced solid tumors and MP0533 for AML.
Cooperation and development partnerships
Collaborations for the joint development, manufacturing and marketing of DARPin programs, in particular with Orano Med and previously with Novartis and AbbVie.
Trust & reputation

ranQ Trust Score of Molecular Partners AG: 4.5 out of 5.0

Trust Score4.5/ 5.0

Excellent

x

Data basis 100% · As of October 2026

Molecular Partners AG scores 80.2 out of 100 points in the Reputation area of the ranQ Trust Score. This area carries 42% of the weighting.
x
CriterionValueWeight
  • Review quality: The average rating across all connected sources, smoothed against the industry mean. So 5.0 stars from three reviews do not outrank 4.7 from three hundred.80.724%
  • Review volume: The number of reviews across all sources. The scale is logarithmic: the first reviews count the most, and the maximum is reached at 50 reviews.63.210%
  • Review recency: The age of the most recent review. Two-year-old reviews deliberately sit in the middle, because that is normal for Swiss SMEs. Only after three years without a new voice does the value drop markedly.100.08%
Molecular Partners AG scores 95.8 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.100.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.96.07%
Molecular Partners AG scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
Molecular Partners AG scores 88.4 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.76.74%
Qualifications+0.00

Molecular Partners AG reaches a ranQ Trust Score of 4.5 out of 5.0 — rated «Excellent». The rating draws, among other things, on 4.9 out of 5 stars from 11 customer reviews. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Reviews

Aggregated rating

Aggregated rating
4.9
of 5

Aggregated from 11 reviews across all connected sources

Sources
GGoogle4.911
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Press

Media

July 17, 2026Media
Forschung: Molecular Partners meldet Fortschritte mit MP0317 bei Gallengangkrebs
fuw.ch
July 1, 2026Media
Molecular Partners und Orano starten erste Patientenbehandlung
cash.ch
July 1, 2026Media
Erste Patienten erhalten Wirkstoff von Molecular Partners
punkt4.info
May 12, 2026Media
Quartalszahlen: Molecular Partners hat höheren Finanzierungsbedarf
fuw.ch
March 13, 2026Media
Einschätzung: Molecular Partners bringt mehr Wirkstoffe mit weniger Geld voran
fuw.ch
March 13, 2026Media
Molecular Partners weitet 2025 Verlust aus
cash.ch

Knowledge

No knowledge articles yet

Once Molecular Partners AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Molecular Partners AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Molecular Partners AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Molecular Partners AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Wagistrasse 14
8952 Schlieren
Opening hours
Mon
08:00 - 17:00
Tue
08:00 - 17:00
Wed
08:00 - 17:00
Thu
08:00 - 17:00
Fri
08:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-112.115.136
Founded
2004 · 22 years
Last commercial register change
June 24, 2026
Employees
101 to 500
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    NS
    Neurimmune Subone AG
    Schlieren
    NA
    Neurimmune AG
    Schlieren
    AT
    Axanton Technology GmbH
    Schlieren
    MA
    Mabylon AG
    Schlieren
    AB
    arcoris bio AG
    Schlieren
    DL
    DAiNA Laboratories AG
    Schlieren
    IB
    Inthera Bioscience AG
    Zurich
    GT
    glaTec, Technologiezentrum an der Empa in Dübendorf
    Dübendorf